Revenues and other income (Tables)

6 Months Ended

Jun. 30, 2018

Revenues and other income

Schedule of revenues

	Six months ended June 30,
	2018		2017
	(Euro, in thousands)
Recognition of non-refundable upfront payments and license fees	€	52,753	€	30,952
Milestone payments		28,567		25,920
Reimbursement income		558		107
Other revenues		5,705		3,945
Total revenues	€	87,583	€	60,925

Summary of recognition of the upfront, license fees and milestone payments

								IAS 18				IFRS 15		IFRS 15		IAS 18		IAS 18		IFRS 15
Agreement		Consideration		Consideration		Collaboration start date		Outstanding balance in deferred income as at December 31, 2017		Deferred income reclassified from equity following adoption of IFRS 15		Outstanding balance in deferred income as at January 1, 2018	Revenue recognized, six months ended June 30, 2018		Revenue recognized, six months ended June 30, 2018		Revenue recognized, six months ended June 30, 2017		Outstanding balance in deferred income as at June 30, 2018
	(USD, in thousands)		(Euro, in thousands)										(Euro, in thousands)
Revenue recognition of considerations received prior to December 31, 2017
Gilead collaboration agreement for filgotinib - Upfront payment	$	300,000	€	275,558		January 2016	€	187,449			€	187,449	€	43,215	€	43,215	€	27,114	€	144,234
Gilead collaboration agreement for filgotinib - Subscription agreement (*)		N.A.	€	39,003	(*)	January 2016	€	26,532			€	26,532	€	6,116	€	6,116	€	3,838	€	20,416
Servier collaboration agreement for osteoarthritis - License fee		N.A.	€	6,000		June 2010	€	5,362	€	(5,362)	€	—	€	—	€	766	€	—	€	—
AbbVie collaboration agreement for CF - Upfront payments	$	45,000	€	34,001		September 2013	€		€	14,872	€	14,872	€	3,422	€	—	€	—	€	11,450
Total upfront and license fees:							€	219,343	€	9,510	€	228,853	€	52,753	€	50,097	€	30,952	€	176,099
Gilead collaboration agreement for filgotinib - Milestone payments	$	70,000	€	64,435		January 2016			€	43,832	€	43,832	€	10,105	€	—	€	9,354	€	33,727
AbbVie collaboration agreement for CF - Milestone payments	$	77,500	€	68,310		September 2013			€	29,878	€	29,878	€	6,875	€	—	€	16,566	€	23,003
Total milestones:									€	73,710	€	73,710	€	16,980	€	—	€	25,920	€	56,730
Total :							€	219,343	€	83,220	€	302,563	€	69,734	€	50,097	€	56,872	€	232,829
Revenue recognition of considerations in the six months ended June 30, 2018
Gilead collaboration agreement for filgotinib - Milestone payments	$	15,000	€	12,418		January 2016							€	5,918	€	12,418	€	—	€	6,500
AbbVie collaboration agreement for CF - Milestone payments	$	10,000	€	8,548		September 2013							€	5,669	€	8,548	€	—	€	2,879
Total milestones:													€	11,587	€	20,966	€	—	€	9,379
Grand total :							€	219,343	€	83,220	€	302,563	€	81,321	€	71,063	€	56,872	€	242,208

Schedule of other income

	Six months ended June 30,
	2018		2017
	(Euro, in thousands)
Grant income	€	825	€	424
Other income		13,464		11,682
Total other income	€	14,289	€	12,106